Impact d’un réseau de centre de référence pour le diagnostic et la prise en charge des patients atteints de sarcomes en France depuis 2010

[1]  F. Bertucci,et al.  1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network , 2022, Annals of Oncology.

[2]  J. Blay,et al.  Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan , 2022, Cancer.

[3]  J. Blay,et al.  No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome? , 2022, Cancers.

[4]  R. Maki,et al.  SELNET Clinical practice guidelines for bone sarcoma. , 2022, Critical reviews in oncology/hematology.

[5]  M. Toulmonde,et al.  Improving at a nationwide level the management of patients with sarcomas with an expert network. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Stevenson,et al.  Impact of the national sarcoma guidelines on the prevalence and outcome of inadvertent excisions of soft tissue sarcomas: An observational study from a UK tertiary referral centre , 2021, European Journal of Surgical Oncology.

[7]  C. M.,et al.  SELNET clinical practice guidelines for soft tissue sarcoma and GIST. , 2021, Cancer treatment reviews.

[8]  S. Sleijfer,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Sleijfer,et al.  Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Grimer,et al.  Regional variation in the survival of patients with a soft-tissue sarcoma of the extremity and trunk wall under a centralized care system : what has been the impact of national policies in the UK? , 2021, The bone & joint journal.

[11]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Blay,et al.  Determinants of the access to remote specialised services provided by national sarcoma reference centres , 2021, BMC cancer.

[13]  David M. Thomas,et al.  Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities , 2021, Cancer.

[14]  R. Grimer,et al.  Impact of NICE guidelines on the survival of patients with soft-tissue sarcomas. , 2021, The bone & joint journal.

[15]  J. Blay,et al.  Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network , 2020, medRxiv.

[16]  R. Grimer,et al.  Inadvertent excision of malignant soft tissue tumours , 2019, EFORT open reviews.

[17]  J. Blay,et al.  Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database , 2019, Annals of Surgical Oncology.

[18]  J. Blay,et al.  Surgery in reference centers improves survival of sarcoma patients: a nationwide study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. A. van der Hage,et al.  Increased survival of non low-grade and deep-seated soft tissue sarcoma after surgical management in high-volume hospitals: a nationwide study from the Netherlands. , 2019, European journal of cancer.

[20]  J. Martín-Broto,et al.  Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). , 2018, The oncologist.

[21]  A. Gavin,et al.  Treatment challenges in and outside a network setting: Soft tissue sarcomas. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  J. Blay,et al.  Networking in rare cancers: What was done, what's next. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  J. Blay,et al.  The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group , 2018, PloS one.

[24]  F. Bertucci,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  B. Bjerkehagen,et al.  The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma , 2017, Acta orthopaedica.

[26]  J. Blay,et al.  Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort) , 2017, PloS one.

[27]  I. Judson,et al.  UK guidelines for the management of soft tissue sarcomas , 2016, Clinical Sarcoma Research.

[28]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  Seiichi Hirota,et al.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines , 2015, Gastric Cancer.

[30]  J. Blay,et al.  Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  J. Blay,et al.  Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions , 2012, BMC Health Services Research.

[32]  J. Blay,et al.  Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing , 2011, PloS one.

[33]  M. Montesco,et al.  STUDY PROTOCOL Open Access Study protocol A European project on incidence, treatment, and , 2022 .

[34]  J. Blay,et al.  Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region , 2010, BMC Cancer.

[35]  C. Fisher,et al.  Histopathological Diagnostic Discrepancies in Soft Tissue Tumours Referred to a Specialist Centre , 2009, Sarcoma.

[36]  A. Daigeler,et al.  Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten , 2008, Der Chirurg.

[37]  Cyril Fisher,et al.  Soft-tissue sarcomas in adults. , 2005, The New England journal of medicine.

[38]  M. Erlanson,et al.  The Scandinavian Sarcoma Group Register 1986–2001 , 2004, Acta orthopaedica Scandinavica. Supplementum.

[39]  M. Reed,et al.  An audit of the management of soft tissue sarcoma within a health region in the UK. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[40]  H. Hoekstra,et al.  Soft tissue sarcoma—Compliance with guidelines , 2001, Cancer.

[41]  A. Rydholm,et al.  Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register , 2001, Acta orthopaedica Scandinavica.